D. Osborne
Directeur Financier/CFO chez Melt Pharmaceuticals, Inc.
Profil
D.
Bradford Osborne is currently the Chief Financial Officer at Melt Pharmaceuticals, Inc. Prior to this, he worked at Precigen, Inc. as the Principal Accounting Officer & VP-Finance from 2011 to 2021.
Postes actifs de D. Osborne
| Sociétés | Poste | Début |
|---|---|---|
Melt Pharmaceuticals, Inc.
 Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN. | Directeur Financier/CFO | 01/02/2022 |
Anciens postes connus de D. Osborne
| Sociétés | Poste | Fin |
|---|---|---|
| PRECIGEN, INC. | Directeur Financier/CFO | 10/06/2021 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PRECIGEN, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Melt Pharmaceuticals, Inc.
Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN. | Health Technology |
